Clinical Trial of Teriparatide in Japan

Status:

COMPLETED

Clinical Trial of Teriparatide in Japan

Lead Sponsor:

Eli Lilly and Company

Conditions:

Osteoporosis

Eligibility:

FEMALE

55+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.

Eligibility Criteria

Inclusion

Japanese women with primary osteoporosis
Postmenopausal women aged at least 55 years
Patients with a high risk for fracture

Exclusion

History of metabolic bone disorders other than osteoporosis
History of any secondary causes of osteoporosis
History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated
Severe or chronically disabling conditions other than osteoporosis

Key Trial Info

Start Date :

February 1 2005

Trial Type :

INTERVENTIONAL

End Date :

March 1 2006

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT00191867

Start Date

February 1 2005

End Date

March 1 2006

Last Update

November 6 2007

Active Locations (6)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (6 locations)

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician

Hiroshima, Japan

Hyōgo, Japan

Kagoshima, Japan

Nagano, Japan

Trial Details

Trial ID

NCT00191867

Start Date

February 1 2005

End Date

March 1 2006

Last Update

November 6 2007

Status: